Loading
Pfizer to invest in adult stem-cell treatment for eyes
Facebook Twitter Google+ Pinterest Addthis

.- The pharmaceutical giant Pfizer has announced that it is funding a new adult stem-cell treatment that could treat diabetes-induced retinal damage, a leading cause of blindness.

Forbes Magazine says that Pfizer is funding the creation of a San Diego biotech company named EyeCyte to develop stem-cell treatments for eye diseases. The company will base its work upon Scripps Research Institute ophthalmologist Martin Friedlander’s research involving stem-cells from blood and bone marrow. EyeCyte will receive about $3 million from Pfizer, which in return has the right of first refusal regarding the new company’s products.

In animal experiments, adult stem-cells have shown a remarkable ability to target and repair damaged blood vessels in the eye, which are a key problem in diabetic eye disease and macular degeneration.

"It is unbelievable. These cells know where to go and they target the site of injury," said Friedlander, according to Forbes. He said that in his lab he has cured mice “10 times over,” but noted it is unknown whether the treatment will help people.

Friedlander had approached Pfizer to fund his research because academic settings and government grants support basic research and not applied-process development.

“Pfizer has put its flag in the ground that there is future in regenerative medicine," said Corey Goodman, president of the Pfizer's biotechnology unit. "The eye is a very good place to be starting--it is an isolated organ, and there is a huge need."

Stem-cell harvesting for any possible future treatment for people with blood-vessel damage in the eye could require only that a patient go to the doctor and leave a blood sample. After adult stem-cells are isolated in the lab over a few hours, the patient would return and receive an injection of his or her cells into the eye.

A successful treatment could delay further blood-vessel damage and preserve eyesight for years.

Mohammad A. El-Kalay, EyeCyte chief executive and a previous member of several cell-therapy companies, said he “got very excited” about the technology when he first heard of it four years ago because it appeared there could be enough cells in one patient’s blood to treat the eyes without having to grow more cells in the lab.

El-Kalay stated that the company aims to have a treatment ready for human trials within three years.

Ads by AdsLiveMedia(What's this?)

* The number of messages that can be online is limited. CNA reserves the right to edit messages for content and tone. Comments and opinions expressed by users do not necessarily reflect the opinions or beliefs of CNA. CNA will not publish comments with abusive language, insults or links to other pages

RESOURCES »

Ads by Google (What's this?)
Ads by Google

Featured Videos

Syrian Refugee, Sara, 14, Before Meeting Pope
Syrian Refugee, Sara, 14, Before Meeting Pope
Ebola orphans thousands of children in West Africa
One year after Haiyan: Philippines rebuilds homes, lives
An Indian contribution to the Vatican's Synod on the Family
Christ Cathedral CNA video Sept 2014
Alejandro Bermudez of CNA accepts ice bucket challenge
'The Real Albania,' remembering those who fled
Pope Francis in Albania, "one of the most important visits of the post-communist era in Albania"
Pope Francis greets paralyzed man who risked all to see him
Franciscans on the banks of the Tiber in Rome, working for the New Evangelization
Pilgrimage from Czech Republic to Assisi and Rome for intentions
Testimony of young Indian who met Pope in Korea
Preparations of the Closing Mass of 6th Asian Youth Day
Missionary of Charity, Korea
Testimony of Christian Love during Pope's Visit to Korea
Religious Sisters in South Korea react to Pope Francis kissing a baby
Warm atmosphere during Holy Mass at Daejeon World Cup Stadium
Images inside Pope Francis flight to South Korea
The tombs of the early Christians
Missionaries of Africa, called "the White Fathers"
Nov
28

Liturgical Calendar

November 28, 2014

Friday of the Thirty-Fourth Week in Ordinary Time

All readings:
Today »
This year »

Catholic Daily

Gospel of the Day

Lk 21:29-33

Gospel
Date
11/28/14
11/27/14
11/25/14

Daily Readings


First Reading:: Rev 20: 1-4, 11-21:2
Gospel:: Lk 21: 29-33

Saint of the Day

St. Romuald »

Saint
Date
11/28/14

Homily of the Day

Lk 21:29-33

Homily
Date
11/28/14
11/27/14
11/25/14